Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena, Rome 324 -00161, Italy.
Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena, Rome 324 -00161, Italy.
Crit Rev Oncol Hematol. 2024 Oct;202:104464. doi: 10.1016/j.critrevonc.2024.104464. Epub 2024 Jul 31.
Fibroblast Growth Factor Receptors (FGFRs) are emerging as key factors involved in tumorigenesis, tumor microenvironment remodeling and acquired resistance to targeted therapies. Pemigatinib is a Tyrosine-Kinase Inhibitor that selectively targets aberrant FGFR1, FGFR2 and FGFR3. Pemigatinib is now approved for advanced-stage cholangiocarcinoma (CCA) but data suggests that other tumor histotypes exhibit FGFR alterations, thus hypothesizing its potential efficacy in other cancer settings. The present systematic review, based on PRISMA guidelines, aims to synthetize and critically interpret the results of all available preclinical and clinical evidence regarding Pemigatinib use in cancer. In April 2024, an extensive search was performed in PubMed, MEDLINE, and Scopus databases using the keyword "Pemigatinib". Twenty-seven studies finally met all inclusion criteria. The promising results emerging from Pemigatinib preclinical and clinical studies pave the way for Pemigatinib extension to multiple solid cancer settings.
成纤维细胞生长因子受体（FGFRs）是肿瘤发生、肿瘤微环境重塑以及对靶向治疗获得性耐药的关键因素之一。培米替尼是一种酪氨酸激酶抑制剂，选择性针对异常的 FGFR1、FGFR2 和 FGFR3。培米替尼现已获批用于晚期胆管癌（CCA），但数据表明其他肿瘤组织类型存在 FGFR 改变，因此推测其在其他癌症治疗中的潜在疗效。本系统评价基于 PRISMA 指南，旨在综合和批判性地解释所有可用的关于培米替尼在癌症中的应用的临床前和临床证据的结果。2024 年 4 月，在 PubMed、MEDLINE 和 Scopus 数据库中使用关键字“Pemigatinib”进行了广泛的检索。最终有 27 项研究符合所有纳入标准。培米替尼的临床前和临床研究的有前景的结果为培米替尼在多种实体癌症治疗中的扩展铺平了道路。
